Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
2
50%
Ph not_applicable
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
N/A1 (25.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

NCT01310816
completedphase_2

A Phase 2 Study With IPI-926 in Patients With Myelofibrosis

NCT01371617
completednot_applicable

IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

NCT01609179
completedphase_1

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

NCT00761696

Clinical Trials (4)

Showing 4 of 4 trials
NCT01310816Phase 2

A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

Completed
NCT01371617Phase 2

A Phase 2 Study With IPI-926 in Patients With Myelofibrosis

Completed
NCT01609179Not Applicable

IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

Completed
NCT00761696Phase 1

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4